These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 16194199)
1. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. Goudemand J; Scharrer I; Berntorp E; Lee CA; Borel-Derlon A; Stieltjes N; Caron C; Scherrmann JM; Bridey F; Tellier Z; Federici AB; Mannucci PM J Thromb Haemost; 2005 Oct; 3(10):2219-27. PubMed ID: 16194199 [TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study. Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS; Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579 [TBL] [Abstract][Full Text] [Related]
3. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity. Goudemand J; Mazurier C; Marey A; Caron C; Coupez B; Mizon P; Goudemand M Br J Haematol; 1992 Feb; 80(2):214-21. PubMed ID: 1550779 [TBL] [Abstract][Full Text] [Related]
4. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study. Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293 [TBL] [Abstract][Full Text] [Related]
6. In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease. Ver Elst KM; van Vliet HD; Kappers-Klunne MC; Leebeek FW Thromb Haemost; 2004 Jul; 92(1):67-74. PubMed ID: 15213847 [TBL] [Abstract][Full Text] [Related]
7. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. Borel-Derlon A; Federici AB; Roussel-Robert V; Goudemand J; Lee CA; Scharrer I; Rothschild C; Berntorp E; Henriet C; Tellier Z; Bridey F; Mannucci PM J Thromb Haemost; 2007 Jun; 5(6):1115-24. PubMed ID: 17403090 [TBL] [Abstract][Full Text] [Related]
8. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. Lethagen S; Kyrle PA; Castaman G; Haertel S; Mannucci PM; J Thromb Haemost; 2007 Jul; 5(7):1420-30. PubMed ID: 17439628 [TBL] [Abstract][Full Text] [Related]
9. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery. Di Paola J; Lethagen S; Gill J; Mannucci P; Manco-Johnson M; Bernstein J; Nichols WL; Bergman GE Haemophilia; 2011 Sep; 17(5):752-8. PubMed ID: 21689209 [TBL] [Abstract][Full Text] [Related]
10. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Mannucci PM; Tenconi PM; Castaman G; Rodeghiero F Blood; 1992 Jun; 79(12):3130-7. PubMed ID: 1596562 [TBL] [Abstract][Full Text] [Related]
11. A comparative in vitro evaluation of six von Willebrand factor concentrates. Lethagen S; Carlson M; Hillarp A Haemophilia; 2004 May; 10(3):243-9. PubMed ID: 15086321 [TBL] [Abstract][Full Text] [Related]
12. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease. Gill JC; Shapiro A; Valentino LA; Bernstein J; Friedman C; Nichols WL; Manco-Johnson M Haemophilia; 2011 Nov; 17(6):895-905. PubMed ID: 21535320 [TBL] [Abstract][Full Text] [Related]
13. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III. Lethagen S; Berntorp E; Nilsson IM Ann Hematol; 1992 Dec; 65(6):253-9. PubMed ID: 1457586 [TBL] [Abstract][Full Text] [Related]
15. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. Federici AB Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of von Willebrand factor concentrate almost devoid of factor VIII (Wilfactin Gouider E; Klukowska A; Maes P; Platokouki H; Pujol S; Henriet C; Bridey F; Goudemand J Blood Transfus; 2023 Jan; 21(1):83-92. PubMed ID: 35543677 [TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study. Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience. Batty P; Chen YH; Bowles L; Hart DP; Platton S; Pasi KJ Haemophilia; 2014 Nov; 20(6):846-53. PubMed ID: 25102895 [TBL] [Abstract][Full Text] [Related]
19. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma. Lippi G; Franchini M; Salvagno GL; Montagnana M; Poli G; Guidi GC J Thromb Thrombolysis; 2008 Oct; 26(2):150-3. PubMed ID: 17786534 [TBL] [Abstract][Full Text] [Related]
20. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease. Budde U; Metzner HJ; Müller HG Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]